Cargando…

FRI150 Individualized And Shorter Follow-up With Immunohistochemical Staining In Unilateral Primary Aldosteronism?

Disclosure: H. Gunnarsdottir: None. B.A. Agnarsson: None. S. Jonasdottir: None. J. Gudmundsson: None. G. Birgisson: None. H.Á. Sigurjónsdóttir: None. Indroduction: Clinical significance of specific antibody staining (SAS) for unilateral primary aldosteronism (PA) has been unclear. Individualized fol...

Descripción completa

Detalles Bibliográficos
Autores principales: Gunnarsdottir, Hrafnhildur, Agnarsson, Bjarni A, Jonasdottir, Sigurrós, Gudmundsson, Jón, Birgisson, Guðjón, Sigurjónsdóttir, Helga Á
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554983/
http://dx.doi.org/10.1210/jendso/bvad114.662
_version_ 1785116545464139776
author Gunnarsdottir, Hrafnhildur
Agnarsson, Bjarni A
Jonasdottir, Sigurrós
Gudmundsson, Jón
Birgisson, Guðjón
Sigurjónsdóttir, Helga Á
author_facet Gunnarsdottir, Hrafnhildur
Agnarsson, Bjarni A
Jonasdottir, Sigurrós
Gudmundsson, Jón
Birgisson, Guðjón
Sigurjónsdóttir, Helga Á
author_sort Gunnarsdottir, Hrafnhildur
collection PubMed
description Disclosure: H. Gunnarsdottir: None. B.A. Agnarsson: None. S. Jonasdottir: None. J. Gudmundsson: None. G. Birgisson: None. H.Á. Sigurjónsdóttir: None. Indroduction: Clinical significance of specific antibody staining (SAS) for unilateral primary aldosteronism (PA) has been unclear. Individualized follow-up of PA patients could be in sight. Long-term outcome of patients, classified based on immunohistochemical staining, needs further investigation. Aims: We aimed to assess long-term clinical outcome (using PASO criteria) for unilateral PA, classifying patients based on SAS. Methods: The study was a nationwide observational study, with up to 11 years follow-up, executed in 2007-2016 at Landspitali National University Hospital of Iceland, tertiary referral center. Patients were diagnosed and treated in line with the current guidelines. All unilateral PA patients, ( n=26) age 28-73 years, who underwent adrenalectomy in Iceland during the study period were included. H&E stained tissue slides were stained using specific CYP11B1 and -B2 antibodies. All cases were re-evaluated and classified as adenoma (APA) or non-adenoma (adrenal hyperplasia, unilateral adrenal micronodules (UMN) or aldosterone producing cell clusters (APCC)). Data collection consisted of aldosterone, renin and cortisol values, antihypertensive drug count, potassium supplementation, blood pressure and serum potassium pre-intervention and throughout follow-up and histopathology results post-adrenalectomy. Results: Following SAS, APA was seen in 21 adrenals, APCC in three and UMN in two. Immunohistochemical staining altered histopathological diagnosis in 27% of the patients. Around 80% of each subgroup had partial clinical success. No APA patient with complete clinical success at 12 months (n=4) relapsed during follow-up. Conclusions: We found SAS mandatory for accurate histopathological diagnosis of PA. Our results indicate that a subgroup of APA patients can be discharged safely early. Presentation: Friday, June 16, 2023
format Online
Article
Text
id pubmed-10554983
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105549832023-10-06 FRI150 Individualized And Shorter Follow-up With Immunohistochemical Staining In Unilateral Primary Aldosteronism? Gunnarsdottir, Hrafnhildur Agnarsson, Bjarni A Jonasdottir, Sigurrós Gudmundsson, Jón Birgisson, Guðjón Sigurjónsdóttir, Helga Á J Endocr Soc Cardiovascular Endocrinology Disclosure: H. Gunnarsdottir: None. B.A. Agnarsson: None. S. Jonasdottir: None. J. Gudmundsson: None. G. Birgisson: None. H.Á. Sigurjónsdóttir: None. Indroduction: Clinical significance of specific antibody staining (SAS) for unilateral primary aldosteronism (PA) has been unclear. Individualized follow-up of PA patients could be in sight. Long-term outcome of patients, classified based on immunohistochemical staining, needs further investigation. Aims: We aimed to assess long-term clinical outcome (using PASO criteria) for unilateral PA, classifying patients based on SAS. Methods: The study was a nationwide observational study, with up to 11 years follow-up, executed in 2007-2016 at Landspitali National University Hospital of Iceland, tertiary referral center. Patients were diagnosed and treated in line with the current guidelines. All unilateral PA patients, ( n=26) age 28-73 years, who underwent adrenalectomy in Iceland during the study period were included. H&E stained tissue slides were stained using specific CYP11B1 and -B2 antibodies. All cases were re-evaluated and classified as adenoma (APA) or non-adenoma (adrenal hyperplasia, unilateral adrenal micronodules (UMN) or aldosterone producing cell clusters (APCC)). Data collection consisted of aldosterone, renin and cortisol values, antihypertensive drug count, potassium supplementation, blood pressure and serum potassium pre-intervention and throughout follow-up and histopathology results post-adrenalectomy. Results: Following SAS, APA was seen in 21 adrenals, APCC in three and UMN in two. Immunohistochemical staining altered histopathological diagnosis in 27% of the patients. Around 80% of each subgroup had partial clinical success. No APA patient with complete clinical success at 12 months (n=4) relapsed during follow-up. Conclusions: We found SAS mandatory for accurate histopathological diagnosis of PA. Our results indicate that a subgroup of APA patients can be discharged safely early. Presentation: Friday, June 16, 2023 Oxford University Press 2023-10-05 /pmc/articles/PMC10554983/ http://dx.doi.org/10.1210/jendso/bvad114.662 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Cardiovascular Endocrinology
Gunnarsdottir, Hrafnhildur
Agnarsson, Bjarni A
Jonasdottir, Sigurrós
Gudmundsson, Jón
Birgisson, Guðjón
Sigurjónsdóttir, Helga Á
FRI150 Individualized And Shorter Follow-up With Immunohistochemical Staining In Unilateral Primary Aldosteronism?
title FRI150 Individualized And Shorter Follow-up With Immunohistochemical Staining In Unilateral Primary Aldosteronism?
title_full FRI150 Individualized And Shorter Follow-up With Immunohistochemical Staining In Unilateral Primary Aldosteronism?
title_fullStr FRI150 Individualized And Shorter Follow-up With Immunohistochemical Staining In Unilateral Primary Aldosteronism?
title_full_unstemmed FRI150 Individualized And Shorter Follow-up With Immunohistochemical Staining In Unilateral Primary Aldosteronism?
title_short FRI150 Individualized And Shorter Follow-up With Immunohistochemical Staining In Unilateral Primary Aldosteronism?
title_sort fri150 individualized and shorter follow-up with immunohistochemical staining in unilateral primary aldosteronism?
topic Cardiovascular Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554983/
http://dx.doi.org/10.1210/jendso/bvad114.662
work_keys_str_mv AT gunnarsdottirhrafnhildur fri150individualizedandshorterfollowupwithimmunohistochemicalstaininginunilateralprimaryaldosteronism
AT agnarssonbjarnia fri150individualizedandshorterfollowupwithimmunohistochemicalstaininginunilateralprimaryaldosteronism
AT jonasdottirsigurros fri150individualizedandshorterfollowupwithimmunohistochemicalstaininginunilateralprimaryaldosteronism
AT gudmundssonjon fri150individualizedandshorterfollowupwithimmunohistochemicalstaininginunilateralprimaryaldosteronism
AT birgissonguðjon fri150individualizedandshorterfollowupwithimmunohistochemicalstaininginunilateralprimaryaldosteronism
AT sigurjonsdottirhelgaa fri150individualizedandshorterfollowupwithimmunohistochemicalstaininginunilateralprimaryaldosteronism